WEST LAFAYETTE, Ind., March 31, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that Ron Ellis, president and CEO of Endocyte, will present at the upcoming Leerink Swann Cancer Roundtable Conference on Thursday, April 7th, 2011, at 11:20 a.m. EDT. Mr. Ellis also will be participating on a panel entitled, "First in Class Agents on the Horizon and Novel Platforms for Cancer," at 9:45 a.m. EDT. The conference is being held at the Roosevelt Hotel in New York City.
A live audio webcast of the Company's presentation can be accessed at or under "Events & Presentations" in the Investor Relations section of Endocyte's website at . The webcast will be archived shortly after the live event and a replay will be available on the Company's website for 90 days following the conference.
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
CONTACT: Vickey Buskirk Endocyte Inc. (765) 807-0617 Stephanie Ascher Stern Investor Relations, Inc. (212) 362-1200